• Explore /
  • Poster
  • / Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma.

Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma.

Abstract Poster

Authors

null

Yuan-Kai Shi

Cancer Institute & Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

Yuan-Kai Shi , Mei Dong , Xiao-Nan Hong , Wei-Jing Zhang , Ji-Feng Feng , Jun Zhu , Li Yu , Xiao-Yan Ke , Hui-Qiang Huang , Zhi-Xiang Shen , Yun Fan , Wei Li , Xie-Lan Zhao , Lu-Gui Qiu , He Huang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

ChiCTR-TNC-10000811

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8525)

DOI

10.1200/jco.2013.31.15_suppl.8525

Abstract #

8525

Poster Bd #

5

Abstract Disclosures

Similar Posters

First Author: Jie Xu

First Author: Jonathan W. Goldman

First Author: Lin Gui

First Author: Jie Jin